Valuation : Jade Biosciences, Inc.

Market Cap 1.14B 980M 928M 841M 1.58B 109B 1.59B 11.02B 4.24B 55.3B 4.27B 4.18B 175B P/E 2026 *
-6.13x
P/E 2027 * -6.24x
Enterprise Value 792M 682M 646M 586M 1.1B 75.67B 1.1B 7.67B 2.95B 38.5B 2.97B 2.91B 122B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.21%
Yield 2026 *
-
Yield 2027 * -
1 day-6.53%
1 week-10.10%
Current month-16.25%
1 month-22.92%
3 months+16.62%
6 months+29.08%
Current year+15.94%
1 week 17.53
Extreme 17.53
20.15
1 month 17.53
Extreme 17.53
25
Current year 12.45
Extreme 12.45
28
1 year 6.91
Extreme 6.91
28
3 years 6.56
Extreme 6.565
28
5 years 6.56
Extreme 6.565
28
10 years 6.56
Extreme 6.565
28
Manager TitleAgeSince
Chief Executive Officer 50 2025-04-27
Director of Finance/CFO 38 2025-07-13
Chief Tech/Sci/R&D Officer - 2024-09-30
Director TitleAgeSince
Director/Board Member 50 2025-04-27
Director/Board Member 42 2025-04-27
Chairman 57 2025-04-27
Date Insider Type Main position Quantity % Market Cap. Importance
6/25/26 Free

Director

47,675 0.0966%
2/12/26 Free

General Counsel

196,875 0.4280%
2/12/26 Free

Chief Technology Officer

288,750 0.6277%
Change 5-day change 1-year change 3-year change Capi.($)
-6.53%-10.10%+132.34% - 1.14B
-0.71%-6.35%-2.99%+9.59% 45.48B
+0.21%-2.98%+337.74%+519.55% 43.68B
+1.74%-2.24%+39.82%+20.76% 43.09B
+1.38%-3.28%+6.84%+67.62% 39.4B
-1.44%-5.26%+8.97%+39.76% 31.91B
+0.87%-2.60% - - 17.31B
+0.75%-0.64%+19.75%+110.17% 16.4B
-0.31%-2.78%+10.78%+31.02% 14.24B
+1.93%-3.55%+82.00%+41.17% 13.28B
Average -0.21%-4.23%+70.58%+104.96% 26.59B
Weighted average by Cap. +0.38%-3.69%+74.83%+124.26%

Financials

2026 *2027 *
Net sales - -
Net income -204M -176M -167M -151M -283M -19.51B -285M -1.98B -761M -9.93B -767M -750M -31.36B -231M -199M -189M -171M -321M -22.08B -322M -2.24B -861M -11.23B -868M -849M -35.5B
Net Debt -346M -298M -282M -256M -480M -33.02B -482M -3.35B -1.29B -16.8B -1.3B -1.27B -53.09B -354M -305M -289M -262M -491M -33.79B -493M -3.43B -1.32B -17.19B -1.33B -1.3B -54.32B
Logo Jade Biosciences, Inc.
Jade Biosciences, Inc. is a biotechnology company, which is focused on developing therapies for autoimmune diseases. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.
Employees
55
Date Price Change Volume
26-09-11 $17.89 -6.53% 1,249,196
26-09-10 $19.14 +0.42% 1,224,853
26-09-09 $19.06 -2.01% 1,507,463
26-09-08 $19.45 -2.26% 825,597
26-09-04 $19.90 +0.25% 605,018
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
17.89USD
Average target price
50.12USD
Spread / Average Target
+180.18%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JBIO Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!